- SHORT TITLE
- INTERPRETATION
- REGISTER AND PATENT LIST
- RIGHT OF ACTION
- NOTICE OF COMPLIANCE
- SERVICE
- RELATED PROVISIONS
Patented Medicines (Notice of Compliance) Regulations
SOR/93-133
PATENT ACT
Registration 1993-03-12
Regulations Respecting a Notice of Compliance Pertaining to Patented Medicines
P.C. 1993-502 1993-03-12
His Excellency the Governor General in Council, on the recommendation of the Minister of Consumer and Corporate Affairs, pursuant to subsection 55.2(4)* of the Patent Act, is pleased hereby to make the annexed Regulations respecting a notice of compliance pertaining to patented medicines.
*S.C. 1993, c. 2, s. 4
SHORT TITLE
1. These Regulations may be cited as the Patented Medicines (Notice of Compliance) Regulations.
INTERPRETATION
2. In these Regulations,
“claim for the dosage form” means a claim for a delivery system for administering a medicinal ingredient in a drug or a formulation of a drug that includes within its scope that medicinal ingredient or formulation; (revendication de la forme posologique)
“claim for the formulation” means a claim for a substance that is a mixture of medicinal and non-medicinal ingredients in a drug and that is administered to a patient in a particular dosage form; (revendication de la formulation)
“claim for the medicinal ingredient” includes a claim in the patent for the medicinal ingredient, whether chemical or biological in nature, when prepared or produced by the methods or processes of manufacture particularly described and claimed in the patent, or by their obvious chemical equivalents, and also includes a claim for different polymorphs of the medicinal ingredient, but does not include different chemical forms of the medicinal ingredient; (revendication de l’ingrédient médicinal)
“claim for the medicine itself”[Repealed, SOR/2006-242, s. 1]
“claim for the use of the medicinal ingredient” means a claim for the use of the medicinal ingredient for the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms; (revendication de l’utilisation de l’ingrédient médicinal)
“claim for the use of the medicine”[Repealed, SOR/2006-242, s. 1]
“court” means the Federal Court or any other superior court of competent jurisdiction; (tribunal)
“expire” means, in relation to a patent, expire, lapse or terminate by operation of law; (expiré)
“first person” means the person referred to in subsection 4(1); (première personne)
“medicine”[Repealed, SOR/2006-242, s. 1]
“Minister” means the Minister of Health; (ministre)
“notice of compliance” means a notice issued under section C.08.004 or C.08.004.01 of the Food and Drug Regulations; (avis de conformité)
“patent list” means a list submitted under subsection 4(1); (liste de brevets)
“register” means the register of patents and other information maintained by the Minister in accordance with subsection 3(2); (registre)
“second person” means the person referred to in subsection 5(1) or (2) who files a submission or supplement referred to in those subsections. (seconde personne)
SOR/98-166, s. 1; SOR/99-379, s. 1; SOR/2006-242, s. 1; err. (E), Vol. 140, No. 23; SOR/2008-211, s. 1; SOR/2011-89, s. 1.
Previous Version
REGISTER AND PATENT LIST
3. (1) The following definitions apply in this section and in section 4.
“identification number” means a number, preceded by the letters “DIN”, that is assigned for a drug in accordance with subsection C.01.014.2(1) of the Food and Drug Regulations. (identification numérique)
“new drug submission” means a new drug submission or an extraordinary use new drug submission as those terms are used in Division 8 of Part C of the Food and Drug Regulations, but excludes such a submission that is based solely on the change of name of the manufacturer. (présentation de drogue nouvelle)
“supplement to a new drug submission” means a supplement to a new drug submission or a supplement to an extraordinary use new drug submission as those terms are used in Division 8 of Part C of the Food and Drug Regulations, but excludes such a supplement that is based solely on one or more of the matters mentioned in any of paragraphs C.08.003(2)(b) and (d) to (g) and subparagraphs C.08.003(2)(h)(iv) and (v) of those Regulations. (supplément à une présentation de drogue nouvelle)
(2) The Minister shall maintain a register of patents and other information submitted under section 4. To maintain the register, the Minister may refuse to add or may delete any patent or other information that does not meet the requirements of that section.
(3) If a patent is listed on the register in respect of a new drug submission or supplement to a new drug submission for a drug for which the identification number has been cancelled under paragraph C.01.014.6(1)(a) of the Food and Drug Regulations, the Minister shall delete the patent from the register 90 days after the date of cancellation.
(4) Subsection (3) does not apply if the identification number is cancelled under paragraph C.01.014.6(1)(a) of the Food and Drug Regulations because of a change in manufacturer.
(5) If, after an identification number is cancelled under paragraph C.01.014.6(1)(a) of the Food and Drug Regulations, an identification number is assigned for the same drug, the Minister shall add to the register the patent that was deleted under subsection (3) when the Minister receives the document required by section C.01.014.3 of the Food and Drug Regulations in respect of the drug.
(6) The register shall be open to public inspection during business hours.
(7) No patent on a patent list or other information submitted under section 4 shall be added to the register until after the Minister has issued a notice of compliance in respect of the new drug submission or the supplement to a new drug submission, as the case may be, to which the patent or information relates.
(8) For the purpose of deciding whether a patent, patent list or other information will be added to or deleted from the register, the Minister may consult with officers or employees of the Patent Office.
SOR/98-166, s. 2; SOR/2006-242, s. 2; SOR/2011-89, s. 2.
Previous Version
3.1 (1) The Minister shall not delete from the register a patent on a patent list that was submitted before June 17, 2006, unless
(a) the patent has expired;
(b) a court has, under subsection 60(1) of the Patent Act, declared that the patent is invalid or void;
(c) the identification number assigned to the drug in respect of which the patent is listed is cancelled under paragraph C.01.014.6(1)(a) of the Food and Drug Regulations; or
(d) the patent is found, under paragraph 6(5)(a), not to be eligible for inclusion on the register.
(2) The Minister shall not refuse to add to the register a patent on a patent list that was submitted before June 17, 2006 solely on the basis that the patent is not relevant to the submission for a notice of compliance to which the patent list relates.
SOR/2008-211, s. 2.
4. (1) A first person who files or who has filed a new drug submission or a supplement to a new drug submission may submit to the Minister a patent list in relation to the submission or supplement for addition to the register.